Talaris Therapeutics, Inc.

NasdaqGM:TALS Voorraadrapport

Marktkapitalisatie: US$553.2m

Talaris Therapeutics Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Mary Fenton

Algemeen directeur

US$2.2m

Totale compensatie

Percentage CEO-salaris20.6%
Dienstverband CEO2.6yrs
Eigendom CEO0.07%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur4.9yrs

Recente managementupdates

Recent updates

Will Talaris Therapeutics (NASDAQ:TALS) Spend Its Cash Wisely?

May 24
Will Talaris Therapeutics (NASDAQ:TALS) Spend Its Cash Wisely?

Is Talaris Therapeutics (NASDAQ:TALS) In A Good Position To Invest In Growth?

Feb 14
Is Talaris Therapeutics (NASDAQ:TALS) In A Good Position To Invest In Growth?

We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

Oct 21
We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

Talaris drops 24% after patient death in late-stage trial for lead asset

Oct 20

Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk

Aug 29

Talaris Therapeutics GAAP EPS of -$0.44

Aug 15

We're Not Very Worried About Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

Jul 06
We're Not Very Worried About Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

Talaris Therapeutics achieves positive results in phase 3 kidney transplant drug trial

Jun 30

Talaris Therapeutics (NASDAQ:TALS) Is In A Good Position To Deliver On Growth Plans

Mar 23
Talaris Therapeutics (NASDAQ:TALS) Is In A Good Position To Deliver On Growth Plans

Talaris Therapeutics EPS beats by $0.49

Jun 14

Analyse CEO-vergoeding

Hoe is Mary Fenton's beloning veranderd ten opzichte van Talaris Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2023n/an/a

-US$75m

Mar 31 2023n/an/a

-US$78m

Dec 31 2022US$2mUS$455k

-US$74m

Sep 30 2022n/an/a

-US$70m

Jun 30 2022n/an/a

-US$64m

Mar 31 2022n/an/a

-US$57m

Dec 31 2021US$2mUS$340k

-US$48m

Compensatie versus markt: De totale vergoeding ($USD 2.21M ) Mary } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).

Compensatie versus inkomsten: De vergoeding van Mary is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Mary Fenton (59 yo)

2.6yrs

Tenure

US$2,209,223

Compensatie

Ms. Mary Kay Fenton has been Chief Financial Officer at Talaris Therapeutics, Inc. since March 2021 and serves as its Treasurer and has been its Interim CEO and President since May 26, 2023. She had been a...


Bestuursleden

NaamPositieTenureCompensatieEigendom
Suzanne Ildstad
Founder21.7yrsUS$1.33m11.88%
$ 65.7m
Mark McDade
Independent Director4.9yrsUS$130.42k0%
$ 0
Geoff MacKay
Independent Director4.9yrsUS$135.05k0%
$ 0
Sapna Srivastava
Independent Director2.8yrsUS$137.92k0%
$ 0
Francois Nader
Independent Chairman4.9yrsUS$175.92k0.90%
$ 5.0m
Sandip Agarwala
Independent Director4.9yrsUS$130.42k0%
$ 0
Karen Smith
Independent Director1.4yrsUS$249.58k0%
$ 0
Gaurav Shah
Independent Director2.8yrsUS$126.92k0%
$ 0

4.9yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TALS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).